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Abstract
Background: Recent evidence suggests that lipid pathway is altered in many human tumours. In Burkitt lymphoma this is
reflected by the presence of lipid droplets which are visible in the cytoplasm of neoplastic cells in cytological preparations.
These vacuoles are not identifiable in biopsy section as lipids are ‘‘lost’’ during tissue processing.
Methods and Results: In this study we investigated the expression of genes involved in lipid metabolism, at both RNA and
protein level in Burkitt lymphoma and in other B-cell aggressive lymphoma cases. Gene expression profile indicated a
significant over-expression of the adipophilin gene and marked up-regulation of other genes involved in lipid metabolism in
Burkitt lymphoma. These findings were confirmed by immunohistochemistry on a series od additional histological samples:
45 out of 47 BL cases showed strong adipophilin expression, while only 3 cases of the 33 of the not-Burkitt lymphoma
category showed weak adipophilin expression (p,0.05).
Conclusions: Our preliminary results suggest that lipid metabolism is altered in BL, and this leads to the accumulation of
lipid vacuoles. These vacuoles may be specifically recognized by a monoclonal antibody against adipophilin, which may
therefore be a useful marker for Burkitt lymphoma because of its peculiar expression pattern. Moreover this peptide might
represent an interesting candidate for interventional strategies.
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Introduction
Burkitt lymphoma (BL) is listed in the World Health Organi-
zation (WHO) classification of tumours of haematopoietic and
lymphoid tissues as an ‘aggressive B-cell non-Hodgkin lympho-
ma’(B-NHL) [1]. Based on epidemiological features, BL is
subdivided into three variants: endemic, sporadic and immuno-
deficiency-associated. While the Epstein–Barr virus (EBV) is
associated with 98% of the endemic BL, it is seen only in 20%
of sporadic cases, and 30–40% of immunodeficiency-associated
cases [2]. Histologically BL is characterized by a monotonous
infiltrate of medium-sized blastic lymphoid cells that show round
nuclei with clumped chromatin and multiple nucleoli and by the
presence of a ‘starry sky’ pattern. On fine needle aspiration
cytology (FNAC), BL shows very typical lipidic vacuoles in the
cytoplasm of lymphoid cells which represents a diagnostic
hallmark [3]. Unfortunately, these vacuoles cannot be seen on
histological preparations because during waxing and fixation they
are largely lost from tissues, and a combination of several
diagnostic techniques (such as morphology, immunophenotyping
or genetic analysis) is necessary to achieve the diagnosis of BL [1].
The tumour cells are positive for CD79a, CD20, CD10, BCL6,
CD38, and are negative for BCL2, Mum-1, CD44 and CD138.
The proliferation fraction measured by Ki-67 is nearly 100% [2].
At molecular level, BL is characterized by the chromosomal
rearrangement of MYC, in the form of reciprocal translocation
juxtaposing the MYC gene at 8q24, to the immunoglobulin heavy
chain (IGH) locus at 14q32, or the IGK (2p11) or IGL (22q11) light
chain loci [2].
The presence of lipid vacuoles in the cytoplasm of BL cells on
FNAC may suggest that biosynthesis of lipids and other
macromolecules is altered in BL. Previous study has found that
lipogenic pathway is activated in some tumours (i.e. hepatocellular
carcinoma, clear cell renal carcinoma, adenocarcinoma of the
colon, sebaceous tumours) [4–5]. In contrast to normal cells,
neoplastic cells rely mainly on anaerobic glycolysis, a phenomenon
known as Warburg effect [5]. To sustain the rapid proliferation
and to counteract the hostile environment, cells must increase the
rate of metabolic reactions to provide adenosine triphosphate,
lipids, nucleotides and amino acids necessary for daughter cell
production [6–7]. A recent paper on lipid metabolism in B-NHL
has shown dysregulation of fatty acid synthesis and increase of
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glycolysis in these tumours, suggesting fatty acid synthase enzyme
as a candidate for molecular target therapy [8].
The present study was designed to analyse the lipid metabolism
in BL and to identify a novel possible marker. We investigated by
gene expression profile (GEP) the genes involved in the lipogenic
pathway in 13 BL and 20 diffuse large B-cell lymphoma (DLBCL)
cases. We observed differences in lipid metabolism between BL
and DLBCL and identified adipophilin (adipocyte-differentiation-
related protein) as the only member of the Perilipin, Adipholin,
Tail-interacting protein of 47 kDa (TIP47) (PAT)-proteins family
strongly expressed in BL [9]. The GEP results were validated on a
series of additional cases classified according to the recent
algorithm proposed by Naresh et al. [10] by immunohistochem-
istry, using a monoclonal antibody against the adipophilin to
confirm lipid accumulation in standard formalin-fixed paraffin-
embedded samples [4]. We observed that 45 out of 47 cases of BL
showed positivity for adipophilin whereas only 3 out of 33 cases of
the not-BL category were adipophilin-positive. These results
suggest adipophilin as a novel marker for BL.
Materials and Methods
Ethics Statement
Ethics approval for this study was obtained from the Institu-
tional Review Board at the University of Siena (Italy) and from the
Ethics and Research Committee at the Lacor Hospital (Uganda).
Informed written consent was obtained in all cases.
Case Selection
A total of sixty formalin-fixed and paraffin-embedded specimens
were investigated at the Department of Human Pathology and
Oncology, Anatomical Pathologic Section, University of Siena,
Italy; the cases had been accrued locally and from Lacor Hospital,
Uganda. The initial diagnosis of these cases was: BL in 43, diffuse
large B-cell lymphoma (DLBCL) in 30 and B-cell lymphoma
unclassifiable with features intermediate between DLBCL and BL
(DLBCL/BL) in 7 [11].
Figure 1. Classification of cases according to the algorithm proposed by Naresh et al. After the revision of 43 BL, 30 DLBCL and 7 DLBCL/BL
cases, 47 BL and 33 not-BL cases were identified.
doi:10.1371/journal.pone.0044315.g001
Table 1. Genes involved in lipid metabolism in BL other than PLIN2.
Probe Set ID p-value Unigene (Avadis) Gene Symbol Gene Title Regulation Entrez Gene
200831_s_at 0,006725255 Hs.558396 SCD stearoyl-CoA desaturase
(delta-9-desaturase)
down 6319
211708_s_at 9,94E-04 Hs.558396 SCD stearoyl-CoA desaturase
(delta-9-desaturase)
down 6319
212218_s_at 0,033671293 Hs.83190 FASN fatty acid synthase up 2194
220232_at 0,009198004 Hs.379191 SCD5 stearoyl-CoA desaturase 5 up 79966
223437_at 3,85E-06 Hs.103110 PPARA peroxisome proliferator-activated
receptor alpha
down 5465
223438_s_at 1,79E-05 Hs.103110 PPARA peroxisome proliferator-activated
receptor alpha
down 5465
226978_at 3,51E-07 Hs.103110 PPARA peroxisome proliferator-activated
receptor alpha
down 5465
231768_at 0,001676206 Hs.414880 USF1 upstream transcription factor 1 up 7391
doi:10.1371/journal.pone.0044315.t001
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Histological and Immunohistochemical Studies
The slides were reviewed by two expert haematopathologists
(LL, SL) and classified according to the scoring system recently
designed by Naresh et al. [10] for aggressive B-cell lymphomas
which distinguishes BL and not-BL. In fact, from a practical
standpoint it is more beneficial to focus on two categories, given
that the prognosis for the DLBCL/BL is uniformly poor [10].
According to the algorithm, we identified 47 BL and 33 not-BL
cases (Figure 1). Histological sections (4-mm thick) were placed on
positively charged glass slides (ProbeOn Plus; Fisher Scientific,
Pittsburgh, PA, USA). The staining was performed on Bond Max
automated immunostainer (Leica Microsystem, Bannockburn, IL,
USA), with adipophilin antibody (pre-dilute AP 125; ProgenBio-
technik GmbH Maabstrasse Heidelberg, Germany) with controls
in parallel. No epitope retrieval was used. Ultravision Detection
System using anti-Polyvalent HRP (LabVision, Fremont, CA,
USA) and diaminobenzidine (DAB, Dako, Milan-Italy) as
chromogen was used. The pattern of immunostaining as well as
the labelling intensity was evaluated independently in each of the
80 cases. The statistical association between the distribution of
expression of adipophilin and the diagnostic category (BL and not-
BL) was analysed using x2–test and Fisher’s exact test, with
P,0.05 considered as being statistically significant.
Gene Expression Analysis
We analyzed GEP data of 13 BL and 20 DLBCL (10 GCB-type
and 10 ABC-type), previously generated by using the Affymetrix
HG-U133 2.0 plus microarray (Affymetrix, Inc. http://www.
affymetrix.com/support/index.affx) and available at http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc =GSE26673
(GSE26673). For technical details, see reference 12 [12]. In
particular, we focused on the expression of ADFP (PLIN2),
identified by a specific probe set in the HG-U133 2.0 plus
GeneChip (209122_at). In addition, we studied the expression of
genes whose activity is known to be related to lipid metabolism,
such as, SCD, SCD5, FASN, USF1, PPARA, and represented in the
microarray by the following probe sets: 200831_s_at,
211708_s_at, 220232_at, 212218_s_at, 231768_at, 223437_at,
223438_s_at, 226978_at. Further details on patients as well as on
GEP generation were previously reported [9]. Supervised analysis
and hierarchical clustering were performed as previously described
by using GeneSpring GX11.0 platform (Agilent, USA) [9.12].
Additional statistical analyses were carried on with the StatView
5.0 software package (SAS Institute Inc, Cary, NC). Anova,
unpaired T-Test and when required (specifically, when sample size
was inferior to 10 cases in at least 1 group) a non-parametric
Mann-Whitney (MW) were adopted for GEP data analyses and, in
particular, for comparing ADFP expression in different subgroups.
The limit of significance for all analyses was defined as P,0.05;
two-sided tests were used in all calculations.
Results
ADFP (PLIN2) Gene is More Expressed in Burkitt
Lymphoma than in DIFFUSE Large B-cell Lymphoma
A previous GEP study on BL cases revealed that adipophilin is
the only member of the PAT-proteins family expressed in BL [9].
Using the same set of data, we measured the expression of ADFP in
BL and DLBCLs and found a significant over-expression in the
former. Specifically, BL presented significant higher level than
both germinal center (GCB)-DLBCL (p= 0.04) and activated B-
cell (ABC)-DLBCL (p= 0.03), while no difference was recorded
among the DLBCL subtypes (Figure 2). Moreover, supervised
analysis revealed that 5 other genes involved in lipid metabolism
were differentially expressed (fold change .2; p,0.05) in BL and
DLBCL. While FASN, SCD5 and USF1 were up-regulated in BL,
SCD and PPARA were up-regulated in DLBCLs. (Figure 3;
Table 1).
Figure 2. ADPF gene over-expression in BL compared to DLBCL. Box plots represent the values distribution across the three considered
categories (A); the extremities of the boxes indicate the first and third quartile. The horizontal lines inside the boxes indicate median values; outlier
values are indicated by blue dots. Histograms represent the mean expression values in the three groups (B).
doi:10.1371/journal.pone.0044315.g002
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Figure 3. Over-expression of genes involved in lipid metabolism in BL. SCD5, FASN and USF1 are up-regulated in BL; SCD and PPARA are up-
regulated in DLBCLs.
doi:10.1371/journal.pone.0044315.g003
Table 2. Adipophilin expression, including intensity of staining and pattern of expression.
Histotype N. positive (%) N. negative (%) Intensity of staining Pattern of expression
BL 45 (96%) 2 (4%) strong single or multiple droplets into the cytoplasm, clustering
around the outer nuclear membrane
not-BL 3 (9%) 30 (91%) weak single, very small droplets into the cytoplasm
BL: Burkitt lymphoma; N.: number of cases; %: percentage.
doi:10.1371/journal.pone.0044315.t002
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Adipophilin is Strongly Expressed in Burkitt Lymphoma
Cases
To confirm GEP results, adipophilin expression was investigat-
ed by immunohistochemistry in BL and not-BL cases, classified
according to the recent algorithm proposed by Naresh et al. [10].
Distinct patterns of adipophilin expression, highlighting lipid
vacuoles, were observed among the two different categories of
lymphoma. A strong immunoreactivity, characterized by single or
multiple droplets in the cytoplasm and clustering of these to the
outer nuclear membrane, was observed in 45 out of 47 BL cases
(Figure 4A-B). In these cases, smaller lipid droplets were also
present. Weak positivity characterized by dispersed fine lipid
droplets in the cytoplasm of a small minority of cells was detected
in 3 out of 33 cases of the not-BL category (Figure 4C-D). 30 out of
33 not-BL cases did not show any expression of adipophilin
(Figure 4E-F). Macrophages showed a granular staining within the
cytoplasm, and this served as an internal positive control. The
evaluation of immunohistochemical expression of adipophilin is
summarized in table 2. The proportion of cases positive for
adipophilin expression was significantly higher (p,0.05) in BL
cases than in the not-BL cases.
Figure 4. Adipophilin immunostain in BL and not-BL cases. (A) BL is characterized by medium-sized cells with a monotonous cohesive pattern
of growth, round nuclei with finely clumped and dispersed chromatin, a high proliferation rate and ‘‘starry-sky’’ appearance [Haematoxilin-eosin
(H&E), original magnification (O.M.)6200). (B) Neoplastic cells show strong positivity to adipophilin with single or multiple droplets in the cytoplasm,
sometimes clustering the outer nuclear membrane (inset); the internal positive control is represented by macrophages which show granular positivity
in the cytoplasm (arrows) (Adipophilin stain, O.M.6200; inset, O.M.6400). (C) An aggressive B-cell lymphoma with diffuse proliferation of medium- to
large-sized cells with irregular nuclear contours and relatively large nucleoli corresponding to morphological score 1 according to the Naresh et al.
scoring system is shown. Few small lymphocytes and starry-sky macrophages are also present (H&E, O.M.6200). (D) Adipophilin immunostain on the
case depicted in figure C with neoplastic cells showing weak positivity characterized by singly scattered fine lipid droplets in the cytoplasm
(Adipophilin stain, O.M.6200). (E) Morphological features of a diffuse large B-cell lymphoma (H&E, O.M.6200). (F) Adipophilin immunostain on the
case depicted in figure E is entirely negative (Adipophilin stain, O.M.6200).
doi:10.1371/journal.pone.0044315.g004
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Interestingly, the three cases of the not-BL category that showed
weak, fine positivity were characterized by a diffuse proliferation of
medium- to large-sized cells with irregular nuclear contours and
relatively large nucleoli. Starry-sky macrophages, mitoses and
apoptosis were prominent, and reactive small lymphocytes were
scanty. This morphological features corresponded to score 1
(range: 0–3) on the algorithm for aggressive B-cell lymphomas
proposed by Naresh et al. [10] and may well represent B cell
lymphoma, unclassifiable with features intermediate between
DLBCL and BL [11].
Discussion
BL is an aggressive B-cell lymphoma with a worldwide
distribution. None of the histological, immunohistochemical or
molecular parameters can be singly used for the diagnosis of BL
and the WHO classification suggests that a combination of several
techniques is necessary [1]. BL is a potentially curable malignancy
if correctly diagnosed, even in the resource-poor settings where BL
is the most common malignancy in paediatric patients [2]. In these
settings, often, performing biopsies is not feasible and the diagnosis
of BL is made on FNAC specimens by identifying the cytoplasmic
lipid vacuoles within the lymphoid cells. However, FNAC is not
always adequate for accurate diagnosis and cytological specimens
do not support further investigations [3]. In this study, we have
attempted to find a novel marker that can detect lipid vacuoles in
histological samples by analysing the lipid metabolism in BL at
both gene and protein level.
GEP showed that FASN, SCD5, USF1 are up-regulated in BL
whereas SCD and PPRA are down-regulated. In addition, we
identified the adipophilin as the only member of PAT-proteins
family to be significantly over-expressed in BL [9]. PAT-proteins is
a family of lipid droplet-associated proteins which also includes
adipophilin, perilipin and TIP47. These proteins are involved in
the formation, maintenance, modification and involution of lipid
droplets [13–14]. While the expression of perilipin is thought to be
restricted to adipocytes and certain steroidogenic cells, adipophilin
and TIP47 are nearly ubiquitously expressed [15]. In particular,
adipophilin is localized to the surface of lipid droplets [4] and is
mainly involved in fatty acids transport and in preserving the
cellular triacylglycerols content [4,16–17]. Tumour cells require de
novo synthesis of lipids for membrane assembly and biosynthesis of
other macromolecules (such as proteins and nucleic acids) to
rapidly dividing [18]. Newly generated fatty acids are promptly
incorporated into membrane lipids and triacylglycerol stores to
accommodate the dramatic proliferative rates of some types of
neoplastic cells [19]. Adipophilin over-expression in BL may thus
reflect the up-regulation of lipogenic pathway and might be related
to the high proliferation rate of this tumour, the fastest growing
tumour in humans.
The results generated by GEP, were validated at protein level
by immunohistochemistry using an antibody against adipophilin.
BL was characterized by strong immunoreactivity and by the
presence of single or multiple droplets in the cytoplasm and
clustering of these droplets to the outer nuclear membrane
whereas DLBCL showed no expression of adipophilin. A weak
labelling may be observed in not-BL cases with features
intermediate between DLBCL and BL. Macrophages showed a
granular staining in the cytoplasm and this may explain the partial
overlap between BL and DLBCL observed at RNA level. These
findings suggest adipophilin as a novel marker that can be useful
for the diagnosis of BL in histological sections and may be a
reliable marker in challenging cases such as DLBCL/BL.
In this paper we gave evidence, for the first time, that lipid
metabolism is altered in BL. The extent to which metabolism plays
a role in lymphomagenesis should not be underestimated. The
change in metabolism cannot be purely attributed to alteration in
allosteric and product/substrate regulation of the metabolic
enzymes [20–24]. Metabolic reprogramming in neoplastic cells
involves numerous genes (i.e. MYC, P53, H1F1, PTEN) that finally
enhances anaerobic glycolysis, lactate production, and biosynthesis
of lipids and other macromolecules [19]. The genes that regulate
these metabolic pathways may thus serve as targets for specific
therapies [23] and, among these, adipophilin may be an
interesting candidate for interventional strategies (e.g. target
therapy or vaccine therapy). A preliminary study has, in fact,
investigated the possible use of adipophilin as a T-cell epitope to
induce antigen-specific cytotoxic T-lymphocytes and mediate
tumour cell lysis [25].
A better knowledge of lipid metabolism alteration in BL can
potentially provide new markers to improve diagnosis and
prognosis as well as novel therapeutic approaches for BL treatment
[26].
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